Drug Profile

Research programme: Glycerol-3-phosphate phosphatase activators - Nimium Therapeutics

Alternative Names: G3PP activators - Nimium Therapeutics

Latest Information Update: 21 Jul 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

21 Jul 2021 NIMIUM Therapeutics entered into partnership agreement with Paraza Pharma to develop glycerol-3-phosphate phosphatase activators to treat Cardiovascular and Metabolic disorders
06 Jul 2021 NIMIUM Therapeutics entered into partnership agreement with adMare BioInnovations to develop hits for glycerol-3-phosphate phosphatase activators
06 Jul 2021 Early research in Cardiovascular disorders in Canada

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com